Acasti Pharma Inc  

(Public, CVE:APO)   Watch this stock  
Find more results for APO
+0.01 (0.89%)
Delayed:   10:28AM EDT
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 1.12 - 1.13
52 week 1.04 - 4.32
Open 1.12
Vol / Avg. 200.00/24,050.00
Mkt cap 119.62M
P/E     -
Div/yield     -
EPS -0.14
Shares 105.86M
Beta 1.46
Inst. own     -

Key stats and ratios

Q4 (Nov '13) 2013
Net profit margin -13601.73% -951.72%
Operating margin -11689.28% -963.78%
EBITD margin - -871.96%
Return on average assets -60.21% -49.41%
Return on average equity -72.76% -56.98%
CDP Score - -


Suite 100, 545 Promenade du Centropolis
+1-450-6864555 (Phone)
+1-450-6862505 (Fax)

Website links


Acasti Pharma Inc. (Acasti) is engaged in developing a product portfolio of long-chain omega-3 phospholipids. Acasti is a majority owned subsidiary of Neptune Technologies and Bioressources Inc. (Neptune). The Company has one operating segment: the development and commercialization of pharmaceutical applications of its licensed rights for cardiovascular diseases. The Company´┐Żs product portfolio includes concentrated phospholipids which functionalize eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Acasti is the producer of anti-dyslipidemic prescription drugs (CaPre), medical foods (Onemia) and over-the-counter (OTC) products (Vectos). During the fiscal year ended February 28, 2011 (fiscal 2011), the Company has completed the development and launched medical food, Onemia.

Officers and directors

Ronald Denis Independent Chairman of the Board
Henri Harland President, Chief Executive Officer, Secretary, Director
Xavier Harland Chief Financial Officer
Pierre Lemieux Ph.D. Chief Operating Officer
Harlan W. Waksal M.D. Executive Vice President - Business and Scientific Affairs
Age: 59
Tina Sampalis MD, Ph.D. Chief Global Strategy Officer
Reed V. Tuckson M.D. Independent Director
Age: 62